Imrunestrant or its salt for use in the treatment and prevention of central nervous system (CNS) metastases in patients with ER+ breast cancer.

Imrunestrant, a SERD, crosses the blood-brain barrier to treat and prevent ER+ breast cancer metastases by degrading estrogen receptors in the brain, addressing the limitations of existing therapies and improving treatment efficacy.

JP2026517821APending Publication Date: 2026-06-02ELI LILLY & CO
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
ELI LILLY & CO
Filing Date
2024-05-02
Publication Date
2026-06-02

Smart Images

  • Figure 2026517821000003
    Figure 2026517821000003
  • Figure 2026517821000004
    Figure 2026517821000004
  • Figure 2026517821000005
    Figure 2026517821000005
Patent Text Reader

Abstract

This disclosure provides compositions and methods comprising imrunestrant or a pharmaceutically acceptable salt thereof for the treatment and prophylaxis of brain metastases. Within such compositions and methods, this disclosure provides the treatment and / or prophylaxis of brain metastases in subjects with ER+ breast cancer.
Need to check novelty before this filing date? Find Prior Art